Transdermal compositions for treating health-related symptoms or healing

Abstract

A transdermal composition can include a cannabis particulate blend including THCA, CBD, and male and female reproductive cells, wherein the cannabis particulate blend has a particle size distribution within a range of about 120 µm to about 400 µm, and wherein the THCA is present in the transdermal composition at from about 0.01 wt% to about 0.5 wt% THCA and the CBD is present in the transdermal composition at from about 1 wt% to about 10 wt% CBD. The transdermal composition can further include from about 1 wt% to about 10 wt% lion's mane mushroom, and from about 50 wt% to about 85 wt% coconut oil and / or butter and about 5 wt% to about 20 wt% beeswax based on a total weight of the transdermal composition. The THCA in this example is prepared to include particles from both the male plant and the female plant.

Description

[0001]TRANSDERMAL COMPOSITIONS FOR TREATING HEALTH-RELATED SYMPTOMS OR HEALING BACKGROUND Cannabinoids is a generic term that relates to several structural classes of compounds found in the cannabis plant. Two of the most notable cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD), though there are over one hundred other currently identified cannabinoids. Unlike THC which is psychoactive and acts on the cannabinoid receptor type 1 (CB1) as a partial agonist, CBD is a negative allosteric modulator of CB1 receptors. The presence of CBD in a formulation can modulate the effect of THC (or any incidental THC that may be present). Though THC is often considered a main active component of cannabis and is not legal for consumption by humans in many places throughout the world, CBD is generally legal for human use in most jurisdictions. Typically, many extracts of the cannabis plant where a certain component is not targeted and enriched may include about 40 wt%, though there are many products with more or less CBD. Application of CBD creams, lotions, ointments, etc., to the skin has provided various health benefits to users. Some formulations may also include THC and / or other cannabinoids for various health reasons. As such, research and development continues in discovering the potential benefits of various cannabinoids in various combinations for the benefit of users. DETAILED DESCRIPTION In accordance with examples of the present disclosure, transdermal compositions, methods of manufacturing the pharmaceutical compositions, and methods of treatment with the pharmaceutical compositions are provided herein. The pharmaceutical compositions of the present disclosure can include both CBD and / or THCA, along with lion’s mane mushroom, blackberry, and coconut oil and / or butter, for example. In some examples, the present disclosure relates to transdermal compositions and can include a cannabis particulate blend including THCA, CBD, and male and female reproductive cells. The cannabis particulate blend can have a particle size distribution within a range of about 120 µm to about 400 µm (or within the range of about 160 µm to about 400 µm). The THCA can be present in the transdermal composition at from about 0.01 wt% to about 0.5 wt% THCA and the CBD can be present in the transdermal composition at from about 1 wt% to about 10 wt% CBD. The transdermal composition can further include from about 1 wt% to about 10 wt% lion’s mane mushroom, from about 1 wt% to about 10 wt% blackberry, and from about 50 wt% to about 85 wt% coconut oil and / or butter. In this example, the THCA and the CBD can include particles from both the male plant and the female plant. In some examples, the transdermal compositions can include one or more additional ingredient(s) selected from about 0.001 wt% to about 0.2 wt% of one or more B-complex vitamins, from about 0.005 wt% to about 0.1 wt% of potassium, from about 1 wt% to about 10 wt% ginkgo leaf, from about 5 wt% to about 20 wt% beeswax, and / or from about 0.1 wt% to about 3 wt% dragon’s blood. In other examples, a method of treating a skin condition can include applying a transdermal composition to a skin region affected by the skin condition, wherein the transdermal composition provides at least transepidermal absorption into the skin through the epidermis. In this example, the transdermal composition can include a cannabis particulate blend including THCA, CBD, and male and female reproductive cells. The cannabis particulate blend can have a particle size distribution within a range of about 120 µm to about 400 µm (or within the range of about 160 µm to about 400 µm). The THCA can be present in the transdermal composition at from about 0.01 wt% to about 0.5 wt% THCA and the CBD can be present in the transdermal composition at from about 1 wt% to about 10 wt% CBD. The transdermal composition can further include from about 1 wt% to about 10 wt% lion’s mane mushroom, from about 1 wt% to about 10 wt% blackberry, and from about 50 wt% to about 85 wt% coconut oil and / or butter. In this example, the THCA and the CBD can include particles from both the male plant and the female plant. In some examples, the transdermal compositions can include one or more additional ingredient(s) selected from about 0.001 wt% to about 0.2 wt% of one or more B-complex vitamins, from about 0.005 wt% to about 0.1 wt% potassium, from about 1 wt% to about 10 wt% ginkgo leaf, from about 5 wt% to about 20 wt% beeswax, and / or from about 0.1 wt% to about 3 wt% dragon’s blood. In other examples, a method of treating a condition within the body beneath the skin, can include applying a transdermal composition to a skin region over body tissue beneath the skin region. In this example, the transdermal composition can include a cannabis particulate blend including THCA, CBD, and male and female reproductive cells. The cannabis particulate blend can have a particle size distribution within a range of about 120 µm to about 400 µm (or within the range of about 160 µm to about 400 µm). The THCA can be present in the transdermal composition at from about 0.01 wt% to about 0.5 wt% THCA and the CBD can be present in the transdermal composition at from about 1 wt% to about 10 wt% CBD. The transdermal composition can further include from about 1 wt% to about 10 wt% lion’s mane mushroom, from about 1 wt% to about 10 wt% blackberry, and from about 50 wt% to about 85 wt% coconut oil and / or butter. In this example, the THCA and CBD can include particles from both the male plant and the female plant. In some examples, the transdermal compositions can include one or more additional ingredient(s) selected from about 0.001 wt% to about 0.2 wt% of one or more B-complex vitamins, from about 0.005 wt% to about 0.1 wt% potassium, from about 1 wt% to about 10 wt% ginkgo leaf, from about 5 wt% to about 20 wt% beeswax, and / or from about 0.1 wt% to about 3 wt% dragon’s blood. In another example, a method of making a transdermal composition can include preparing a cannabis particulate blend with enhanced CBD content, THCA content, and reproductive organ content by freezing both male and female cannabis plants, crushing the male and female cannabis plants, and removing cannabis particulates less than about 120 µm in particle size and greater than about 400 µm in particle size. This method leaves behind the cannabis particulate blend which has a particle size range from about 120 µm to about 400 µm and also has enhanced CBD content, THCA content, and reproductive organ content (compared to the raw crushed cannabis plant particulates prior to removing the particulates below about 120 µm and above about 400 µm). For example, the cannabis particulate blend that remains after the removal process is typically substantially devoid of THC. In further detail, the method can include combining the cannabis particulate blend with lion’s mane mushroom, blackberry, and one or more of coconut oil or coconut butter. In some examples, removing the cannabis particulates that are less than about 120 µm can be carried out using a strainer having a mesh size from about 120 µm to about 160 µm. In other examples, the method can include removing cannabis particulates less than about 160 µm in particle size. In some examples, the transdermal composition can include from about 0.01 wt% to about 0.5 wt% THCA, from about 1 wt% to about 10 wt% CBD, from about 1 wt% to about 10 wt% lion’s mane mushroom, from about 1 wt% to about 10 wt% blackberry, and from about 50 wt% to about 85 wt% coconut oil and / or butter. In some examples, the method can include adding from about 0.001 wt% to about 0.2 wt% of one or more B-complex vitamins, from about 0.005 wt% to about 0.1 wt% potassium, from about 1 wt% to about 10 wt% ginkgo leaf, from about 5 wt% to about 20 wt% beeswax, and / or from about 0.1 wt% to about 3 wt% dragon’s blood. In other words, anywhere from one to all of these additional ingredients can be included in carrying out the method of making the transdermal composition. In each of these examples related to the transdermal compositions and / or the methods thereof, the transdermal compositions can be formulated to penetrate through the skin to treat a condition within the body beneath the skin, such as tissue directly beneath an application site of a skin surface. It is noted that when discussing the transdermal compositions, the methods of manufacture of the transdermal compositions, and / or the methods of treatment using the transdermal compositions, these discussions are considered applicable to other examples whether or not they are explicitly discussed in the context of that example unless expressly indicated otherwise. Thus, for example, when discussing THCA in the context of the transdermal composition, such disclosure is also relevant to and directly supported in context of methods, and vice versa. Furthermore, for simplicity and illustrative purposes, numerous specific details are set forth in order to provide a thorough understanding of the present disclosure. It will be readily apparent however, that the present disclosure can be practiced without limitation to some of these specific details. In other instances, certain methods, systems, materials, and structures have not been described in detail so as not to obscure the present disclosure. In further detail, the transdermal compositions described herein include THCA, CBD, and reproductive cells from both male and female plants, which concentrations can be modulated in concentrations by varying the particle size distribution within the range of about 120 µm to about 400 µm. The THCA, CBD, and the male and female reproductive cells of the cannabis plant can be prepared to form a “cannabis particulate blend,” as defined herein, which excludes or at least substantially excludes particle sizes outside of the 120-400 µm particle size range. In accordance with this, the term “particle size distribution” refers to the particle sizes that remain in the cannabis particulate blend, with at least substantially all other particle sizes being removed. The term “substantially” in this context refers to no more than about 0.1 % of larger particles and / or 0.1 % of smaller particles (by particle count) that would be permitted to remain residually with the cannabis particulate blend in order to fall within the particle size distribution range. Furthermore, it is noted that a narrower particle size distribution that falls wholly within a given particle size distribution range would likewise read on the given particle size distribution range that is enumerated. For example, a particle size distribution of 200 µm to 360 µm would read on a particle size distribution from 120 µm to 400 µm (allowing for up to 0.1% particles on each end of the range). Thus, a particle size distribution refers to the particles that are retained in the cannabis particulate blends of the present disclosure (with very few if any particles outside of this range being permitted to remain). In further detail, in some instances, an “average” particle size will be used, which will typically be well within a particle size distribution range, as the average particle size provides a mean particle size by particle count. Thus, a narrower range of average particle size compared to the entire particle size distribution will typically be used here. With respect to various cannabinoids, it is understood that the cannabinoids CBD and / or THC receive the most attention. However, there are also other cannabinoids with a biogenetic origin that are usually present at lower concentrations in cannabis plants, such as tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabichromenic acid (CBCA), and their common precursor cannabigerolic acid (CBGA). The benefits of these cannabinoids are less well understood, though their chemical structures are known. With that in mind, it has been found that combining CBD with THCA at relatively narrow weight ratios (relative to one another), along with other beneficial compounds, a myriad of health benefits to users can be achieved, both dermally or to local tissue directly beneath the skin where the transdermal composition is applied, and in some instances, more systemically through transdermal delivery to the circulatory system. In some instances, application over various chakras of the body can likewise promote systemic healing. Some transdermal compositions may be prepared that penetrate through the dermis and into the underlying skin tissue. Other transdermal compositions may be prepared that penetrate all the way through the skin to the underlying tissue or to systemic circulation. In some instances, enhanced efficacy and / or skin penetration may take place by the application of heat to the site of body surface application. Dry, healthy human skin typically has a surface temperature from about 30 °C to about 36 °C. When applying heat to a skin site where the transdermal composition has been applied, care should be taken not to apply heat at too great of a temperature boost to avoid burning the skin. Example temperatures that may be used to heat the skin site may be from about 36 °C to about 44 °C, from about 36 °C to about 42 °C, or from about 38 °C to about 42 °C. Heat may be applied by any heating device, such as an electrical heating pad; a chemical reaction- based heating device, e.g., exposure to oxygen or air to generate an exothermic oxidation of iron particles, salts, water, etc.; a radiant heat device, e.g., microwave or infrared; a phase-transition of fluid device, etc. Referring now to the THCA more specifically, in some examples, the THCA can be present in the transdermal composition at from about 0.01 wt% to about 0.5 wt%, from about 0.01 wt% to about 0.3 wt%, from about 0.02 wt% to about 0.2 wt%, from about 0.03 wt% to about 0.3 wt%, or from about 0.03 wt% to about 0.1 wt%. In examples of the present disclosure, the THCA content can be enhanced when forming a cannabis particulate blend by excluding cannabis particles having a particle size below about 120 µm and above about 400 µm, or below about 160 µm and above about 400 µm. Excluding particles outside of these ranges, e.g., from about 120 µm to about 400 µm or from about 160 µm to about 400 µm, reduces or substantially removes the THC content and other materials / compounds that are not particularly beneficial for treating the health- related symptoms and / or healing as described herein. For example, a high concentration of THCA can be found within the particle size ranges of about 160 µm to about 200 µm, whereas THC is often found with particle size ranges from about 35 µm to about 120 µm, and some THC is also found at particle sizes up to about 160 µm. Thus, removing cannabis particle sizes below about 120 µm can substantially reduce the THC content and removing cannabis particles below about 160 µm can even further exclude THC from the cannabis particulate blends used to form the transdermal compositions of the present disclosure. It is notable that not all buds from cannabis plants include THCA, but it may be present in cannabis plants at up to about 30 wt% in cannabinoid content, e.g., 0-30 wt% THCA. THCA, for example, is more likely to be found in raw cannabis than in various extractions and formulations prepared more specifically for human use. Thus, THC and THCA have different chemical structures, with THCA including an additional carboxyl group. Though CBGA is a precursor to many cannabinoids, THCA in particular can be a precursor to THC under the correct conditions. Formula I illustrates example chemical structures for THCA, and Formula II illustrates the chemical structure for THC for comparison, as follows: OH I It is noted that THCA has two isomers, namely THCA-A and THCA-B, each having the carboxylic acid at a different location about the aromatic ring. Unless THCA drops its carboxyl group, THCA is not psychoactive and can be used without any psychoactive effect. Furthermore, the conversion of THCA to THC in vivo is believed to be very limited, and thus, it has limited applicability as a prodrug for THC. As a result, THCA can be delivered internally with little to no psychoactive effect. Even so, as an intact THCA molecule, this compound may be beneficial for treatment of many ailments as a receptor binding compound, and may act as an inhibitor of PC-PLC, COX-1, COX-2, TRPM8, TRPV1, FAAH, NAAA, MGL, DGLα, and anandamide transport. It may also be an agonist of TRPA1 and TRPV2. In greater detail regarding THCA, growers typically only cultivate the female flowers, because when they are pollinated, they decrease their resin yield and then ultimately stop producing their resin yield to develop seeds. Thus, it is common practice to discard the male plants unless they are specifically being used to breed their own strains. In other words, the presence of male plants can compromise the potency of the buds being produced with THCA. However, unlike what is typically done in the industry, it has been found that by including both male and female plants in the transdermal compositions of the present disclosure at a particle size that retains the male and female plant reproductive zones, e.g., at least about 160 µm, a more efficacious transdermal composition can be prepared, particularly for anti-wrinkling and anti-aging applications. In examples of the present disclosure, the THCA may come from any of a number of cannabis sources, but in some examples, at least some of the THCA (and in some cases other cannabinoids) may come from the separation of various particle sizes of the cannabis flower. For example, in collecting THCA, cannabis flowers can be processed through ice water where it is washed in a machine designed for cannabis, and then may be rinsed with water through a series of micron-sized screens, e.g., 400 µm, 220 µm, 160 µm, etc. Certain particle size ranges may be more concentrated in THCA and other particle size ranges may be more concentrated in THC. For example, THC, which often has the side effect of laziness, sleepiness, lethargy, etc., is the compound that is often used recreationally in products like hash (cannabis extract primarily from the resinous glands that line the cannabis plant surface), dab (flash vaporization concentrates of cannabis with 60 wt% to 90 wt% THC), marijuana, etc. In parts of the cannabis plant, including the flower, THC tends to be more concentrated at particle sizes less than about 160 µm, e.g., from about 37 µm to less than about 160 µm. On the other hand, THCA, which does not have these side effects, tends to be more concentrated at particle sizes ranging from about 160 µm to about 400 µm. Thus, in accordance with the present disclosure, as the inclusion of THCA is prioritized over THC, the particle size distribution collected from the cannabis plant can range from about 120 µm to about 400 µm (likely leaving a small amount of THC present), from about 160 µm to about 400 µm (removing all but a de minimis concentration of THC). Furthermore, in the particle size ranges from about 120 µm to about 400 µm or from about 160 µm to about 400 µm, there will also be an enhanced concentration of CBD present, which is also beneficial for treatment and / or healing in accordance with the present disclosure. Thus, in accordance with examples of the present disclosure, the THCA and CBD included in the transdermal compositions described herein can be prepared from male and female cannabis plants that are processed to form a cannabis particulate blend having an particle size distribution from about 120 µm to about 400 µm, from about 160 µm to about 400 µm, from about 160 µm to about 360 µm, from about 180 µm to about 360 µm, or from about 180 µm to about 320 µm. As a point of clarity, the average particle size of the cannabis particulate blend would be well within the about 120 µm to about 400 µm particle size distribution, ranging typically from about 160 µm to about 360 µm or from about 180 µm to about 320 µm by particle count, for example. In further detail, the cannabis particle blend that is rich in THCA and CBD can be prepared to have very few particles having a size less than about 120 µm, less than about 160 µm, less than about 180 µm, or even less than about 200 µm in some instances. With a lower tolerance for the smaller particles within the range, the THC content can likewise be reduced more significantly and / or removed from the cannabis particulate blend, biasing the transdermal compositions with higher concentrations of THCA. For example, the transdermal composition can be prepared so that no more than about 0.1 % of the particles from the cannabis plant have a particle size below about 120 µm, below about 160 µm, below about 180 µm, or below about 200 µm. The cannabis particulate blend that is rich in THCA and CBD can likewise be prepared to have very few particles having a size greater than about 500 µm, greater than about 450 µm, greater than about 400 µm, or greater than about 360 µm. For example, the transdermal composition can be prepared so that no more than about 0.1 wt% of the particles from the cannabis plant have a particle size above about 450 µm, above about 400 µm, or above about 360 µm. In additional detail, the cannabis particulate blend with enriched concentrations of THCA and CBD can be prepared so that both male plant and female plant particles are present, and thus within the ranges described herein regarding particle size, cannabis particulate blends can be prepared that retain both male and female reproductive cells. The particle sizes that can be present to retain reproductive cells may be from about 260 µm to about 400 µm, or from about 280 µm to about 380 µm, for example. In accordance with this, both male and female plant particles can be present within cannabis particulate blends used to prepare the transdermal compositions of the present disclosure. By varying the particle size distribution, there may be more or less THCA and / or more or less male and female reproductive cells present. A higher sub-range within the 120 µm to 400 µm range may include a higher concentration of male and female reproductive cells, e.g., from about 220 µm to about 400 µm, whereas a lower sub-range within the 120 µm to 400 µm range may include a higher concentration of THCA compared to the concentration of male and female reproductive calls, e.g., from about 120 µm to about 300 µm. Though both of these subranges would provide different concentrations of THCA compared to male and female reproductive cells, both formulations would still include a reasonable concentration of both the THCA and the male and female reproductive organs. In further detail regarding the male and female plants used to prepare the cannabis particulate blends of the present disclosure, they may be included at a male cannabis plant to female cannabis plant weight ratio from about 9:1 to about 1:9, from about 5:1 to about 1:5, from about 2:1 to about 1:2, or at about 1:1. Most preparers of cannabis product separate out the male particles, focusing on the female flower particles. However, in accordance with the present disclosure, it has been found that retaining both male and female portions of the cannabis at particle sizes that retain the male and female reproductive cells can provide benefits for skin treatment, anti-aging, healing, and / or other applications. Referring now to the CBD, this cannabinoid can be present at from about 1 wt% to about 10 wt%, from about 1.5 wt% to about 8 wt%, from about 2 wt% to about 8 wt%, or from about 2 wt% to about 6 wt%. In examples of the present disclosure, the CBD content can be enhanced when forming a cannabis particulate blend by excluding cannabis particles having a particle size below about 120 µm and above about 400 µm, or below about 160 µm and above about 400 µm. Excluding particles outside of these ranges, e.g., from about 120 µm to about 400 µm or from about 160 µm to about 400 µm, reduces or substantially removes the THC content and other materials / compounds that are not particularly beneficial for treating the health-related symptoms and / or healing as described herein. For example, a high concentration of CBD can be found within the particle size ranges of about 160 µm to about 280 µm. CBD has a variety of health benefits, including pain relief and anti-inflammatory properties, as the body produces neurotransmitters known as endocannabinoids that bind to cannabinoid receptors. Other reported benefits may include those related to alleviating symptoms of mental health disorders, e.g., mood disorders, depression, anxiety, psychosis, and PTSD-related symptoms. Symptoms related to cancer or cancer treatment can benefit from the presence of CBD, including the treatment of nausea, vomiting, and pain. It may also have some anti-cancer properties. CBD is also neuroprotective against neurological disorders, including a reduction in spasticity in people suffering from multiple sclerosis, and / or a reduction in seizure activity due to a variety of conditions. There is also some data related to improving symptoms related to Parkinson’s disease, Huntington’s disease, autism spectrum disorder, motor disorders, e.g., cerebral palsy, etc. CBD may also have heart benefits, including reducing risks related to high blood pressure, including stroke, heart attack, and metabolic syndrome. For example, CBD may influence the contraction of heart muscle and help widen blood vessels. In further detail, CBD can also assist with substance misuse treatment, glioblastoma, and sleep disorders. In further detail, the transdermal compositions and methods of the present disclosure include a relatively low concentration of CBD and an even lower concentration of THCA (and is also typically devoid or substantially devoid of THC). In some examples, the transdermal compositions of the present disclosure can be prepared to be substantially devoid or even devoid of THC. If an incidental amount of THC is present, it could be present as an impurity, and as such, would typically be present at a lower concentration than the very small amount of THCA that is present in the transdermal compositions. In other examples, THC can be included, but the transdermal compositions of the present disclosure are not intended to provide healing properties due to the psychoactive effect of THC, so to the extent THC is included, it should be included at a concentration that does not substantially interfere with the healing properties provided by the presence of the THCA. That said, these transdermal compositions can provide healing properties when applied to the skin or other body surface topically, and can also provide health benefits systemically and / or to underlying tissue via transdermal delivery. The term “transdermal” herein refers to the active ingredients of at least CBD and THCA traversing the skin to be delivered to underlying tissue or into systemic circulation. Other ingredients may also be transdermally delivered, including the male and female reproductive cells from the cannabis plants, the lion’s mane, the blackberry, and / or any of the other additional components that may be present in the transdermal compositions described herein. In some examples, the transdermal delivery may be in the form of transepidermal delivery, where only traversing of the epidermis is needed, such as in instances where a skin condition is being treated. Thus, the term “transdermal” includes the passage of CBD and THCA (and other components in some instances) through the skin unless the context clearly dictates that the CBD and THCA delivery is transepidermal. Stated another way, the term “transdermal delivery” herein refers to at least transepidermal delivery, and in the context of treating underlying tissue or systemic treatment, transdermal delivery refers to the passage of CBD and THCA through at least a portion of the skin region to which the transdermal composition is applied. In some instances, the transdermal composition may be assisted in traversing the skin by the application of heat. For example, application of heat can assist the efficacy and transdermal properties of some of the other compounds, such as lion’s mane. In some examples, application of heat may convert a portion of the THCA to THC, depending on the temperature and application time. Regarding the lion’s mane mushroom, this component can be included at from about 1 wt% to about 10 wt%, from about 1.5 wt% to about 8 wt%, or from about 2 wt% to about 6 wt%. Lion’s mane mushroom has several health benefits, including benefits related to brain health, particularly in boosting focus and memory, and some evidence indicates it may be effective in preventing or treating Alzheimer's disease and / or Parkinson's disease. Lion's mane is also very high in antioxidants, which is also very effective at inhibiting and / or lowering inflammation in the body. In some examples, other mushrooms can be included in the transdermal composition, including those with overlapping and / or different benefits relative to lion’s mane. Example additional mushrooms that may be present include reishi, chaga, turkey tail, and / or cordyceps, to name a few. The lion’s mane can be added as a lion’s mane powder or particulate product, for example. There are a variety of lion’s mane manufacturers that provide 100% lions mane powder from the lion’s mane mushroom. Alternatively, the lion’s mane may be grown and processed into a particulate or powder for inclusion in the transdermal compositions of the present disclosure. For example, Notably, any of the ingredients described herein may be supplied in powder and / or liquid form from a reputable manufacturer, grown and processed by the formulator, etc. Regarding the blackberry, this can be included in the transdermal composition at from about 1 wt% to about 10 wt%, from about 1.5 wt% to about 8 wt%, or from about 2 wt% to about 6 wt%, for example. Even though blackberries are known as a “superfood” with beneficial vitamins, minerals, fiber, and antioxidants, including blackberry in the transdermal compositions of the present disclosure can provide benefits to the skin, underlying tissue, and / or to the body in general when absorbed through the skin. More specifically, blackberries include many vitamins, minerals, such as vitamins C and K, as the mineral manganese. Blackberries may be beneficial against various forms of cancer and can contribute to a healthy heart, preventing heart disease. Blackberries can also promote brain health. In accordance with examples of the present disclosure, the blackberries may be included in the form of pulverized particles, or may be juiced and stained to remove skin, seeds, etc., and included as a blackberry juice. The coconut oil and / or butter can be included in the transdermal compositions at from about 50 wt% to about 85 wt%, from about 55 wt% to about 80 wt%, or from about 60 wt% to about 80 wt%. Coconut butter is sometimes referred to as coconut manna, coconut meat puree, coconut cream concentrate, or whole coconut flesh puree, and is a spreadable paste made from ground coconut flesh and has a fairly thick viscosity, with a texture and consistency similar to that of various other nut butters, e.g., peanut butter, almond butter, etc. It can be prepared with other additives but typically is prepared without other additives, e.g., 100% coconut flesh, often prepared by blending in mixing equipment, such as a food processor, to achieve a creamy butter. In further detail, coconut butter is high in fatty acids, so it can help keep the skin moisturized, reducing dry skin and wrinkles. Coconut oil, on the other hand, is typically prepared by cold-pressing oil from coconut meat. It is typically a solid at room temperature, and becomes liquid when warmed or heated. Coconut oil can encourage fat burning, exhibit antimicrobial effects, ameliorate seizures, and provide a good antioxidant source. Coconut oil can also reduce symptoms associated with Alzheimer’s and other mental diseases. Both coconut oil and coconut butter are primarily comprised of fat, most of which is saturated fat. Much of the saturated fat is in the form of lauric acid, which can benefit or enhance the presence of HDL cholesterol, which is typically viewed as the “good” cholesterol. Furthermore, lauric acid can be a good skin penetration enhancer, which can provide the transdermal effect of some of the active ingredients in the transdermal compositions of the present disclosure, such as the THCA and the CBD, as well as the lion’s mane, blackberry, and / or the vitamins / minerals that may be present. In addition to the coconut oil and / or butter, which provides the creamy texture and consistency to the transdermal composition as well as transdermal properties, other carrier additives can be included in amounts up to about 20 wt%, for example. Those carrier additives can be included for purposes of enhancing penetration and / or adjusting the texture and / or consistency of the transdermal composition. Example carrier additives include cocoa butter, shea butter, algae body butter, jojoba butter, cupuacu butter, hemp oil, almond oil, sunflower seed oil, olive oil, avocado oil, argan oil, rosehip seed oil, grape seed oil, fish oil, palm oil, anise oil, apricot oil, cassia oil, castor oil, cinnamon oil, clove oil, coriander oil, corn oil, cottonseed oil, eucalyptus oil, lemon oil, lime oil, limonene, nutmeg oil, orange oil, peanut oil, peppermint oil, phenol, pine needle oil, polypropylene glycol, sesame oil, spearmint oil, soybean oil, vegetable oil, abyssinica oil, macadamia nut oil, limnanthes alba seed oil, aloe vera, petrolatum, or a combination thereof. This list is not intended to be exhaustive, but merely a list of example carrier additives that can be included, without limitation. As a more specific example, in some instances, shea butter may be blended with the coconut oil and / or butter to provide a modified consistency, texture, and or viscosity, as well as provide benefits associated with its moisturizing properties and its high levels of vitamin A, vitamin E, and antioxidants. In addition to the THCA, CBD, lion’s mane, blackberry, and coconut oil and / or butter components, there are other additives that can be included in the transdermal compositions and in the methods that utilize the transdermal composition. Examples of such additional additives include B-complex vitamin(s), potassium, ginko leaf, beeswax, and / or dragon’s blood. For example, the transdermal composition can further include from about 0.001 wt% to about 0.2 wt% of one or more B-complex vitamins, from about 0.005 wt% to about 0.1 wt% potassium, from about 1 wt% to about 10 wt% ginkgo leaf, from about 5 wt% to about 20 wt% beeswax, and / or from about 0.1 wt% to about 3 wt% dragon’s blood. All of these other additives can be included, or one or more can be included in the transdermal compositions of the present disclosure. Regarding the B-complex vitamin content, these vitamins can be added via a liquid solution, typically using primarily water as the carrier. For example, the B-complex vitamins added to the transdermal compositions of the present disclosure can be sourced from a liquid solution or suspension carrying one or more B vitamins. The B vitamins may typically be included in the liquid solution or suspension at a weight percent from about 0.1 wt% to about 10 wt% B vitamins. Regardless of the B-complex vitamin source used to provide the B vitamin content to the transdermal compositions of the present disclosure, if included, the B vitamin content can be present at from about 0.001 wt% to about 0.2 wt%, from about 0.005 wt% to about 0.2 wt%, from about 0.01 wt% to about 0.2 wt%, from about 0.001 wt% to about 0.1 wt%, from about 0.005 wt% to about 0.1 wt%, or from about 0.01 wt% to about 0.1 wt% of one or more B-complex vitamins based on total B-complex vitamin content. The B-complex vitamins in particular can include any of the B vitamins, but in particular, the B vitamins can include thiamin (B1), riboflavin (B2), niacin (B3), pyridoxine (B6), folic acid or folate (B9), and / or cobalamin (B12). In some examples, the B vitamins can be in the form of methylated B vitamins, rather than other synthetic forms, such as folic acid or cyanocobalamin. Methylated B vitamins are more universally usable by subjects, including the significant number of the population having the MTHFR gene mutation. Furthermore, in some instances, the liquid solution may carry other compounds (along with the B-complex vitamins), such as vitamin C, vitamin D, vitamin E, vitamin A, etc. For example, if vitamin C is included, in some instances, it may be present at a lesser or greater concentration relative to the B- complex vitamins collectively, e.g., from 0.1 wt% to about 10 wt% vitamin C. The same may be true of any other vitamins that are present in the liquid solution or suspension containing the B-complex vitamins. Likewise, the potassium may typically be included When potassium is included, it can be provided by any of a number of potassium sources, such as potassium chloride, potassium iodide, potassium gluconate, potassium citrate, potassium amino acid complex, potassium bicarbonate, etc. In some examples, the potassium can be provided by a liquid solution or suspension that includes potassium, such solutions of potassium ionic liquid electrolyte having from about 0.1 wt% to about 10 wt% potassium content. Regardless of the potassium source used to provide the potassium content to the transdermal compositions of the present disclosure, if included, the potassium content can be present at from about 0.005 wt% to about 0.1 wt%, from about 0.01 wt% to about 0.1 wt%, from about 0.05 wt% to about 0.1 wt%, from about 0.005 wt% to about 0.05 wt%, or from about 0.01 wt% to about 0.05 wt%, for example. Potassium is an essential mineral that plays a significant role in many body functions, and as many people are deficient in potassium, the addition of potassium can provide additional health benefits if present. Potassium health benefits may include reduction of blood pressure and water retention, protection against stroke, prevention and / or treatment of osteoporosis or kidney stones, to name a few. The ginkgo leaf can be included in the transdermal composition at from about 1 wt% to about 10 wt%, from about 1.5 wt% to about 8 wt%, or from about 2 wt% to about 6 wt%. Ginkgo leaf is different than ginkgo biloba extract and / or ginkgo fruit. Ginkgo leaves are typically harvested when green and then dried for use. Ginkgo leaves contain natural active flavonoids and picrolactones, and are a strong antioxidant, which can be beneficial to human subjects for a variety of reasons. For example, ginkgo leaf can dissolve cholesterol and expand blood vessels, making it a good herb for use against hypertension (high blood pressure) and / or heart disease. Furthermore, ginkgo leaf is associated with improvement in brain dysfunction, arteriosclerosis, dizziness, and / or tinnitus. It may also be effective for treating symptoms associated with Alzheimer’s disease, Parkinson’s disease, memory loss, brain function, e.g., anxiety, etc. Ginkgo leaf can be likewise used for reducing inflammation, supporting vision and eye health, improving symptoms associated with asthma or COPD, reducing headaches and / or migraines, and / or reducing symptoms associated with PMS or sexual dysfunction. Beeswax can also be included at from about 4 wt% to about 20 wt%, from about 5 wt% to about 18 wt%, or from about 6 wt% to about 15 wt%. Beeswax is a natural wax produced by honey bees. Chemically, beeswax primarily includes esters of fatty acids and various long-chain alcohols. An approximate chemical structure for beeswax (understanding there is variability) is C15H31COOC30H61. The main constituents include palmitate, palmitoleate, and oleate esters of long chain aliphatic alcohols, e.g., C30-C32. The molar ratio of triacontanyl palmitate (a wax ester) to cerotic acid, the two main constituents, is about 6:1. There are various forms of beeswax, and any of these forms can be used. For example, there is European beeswax having a saponification value from about 3-5 and there is an Oriental beeswax with a saponification value of about 8-9. The saponification value can be determined by high-temperature gas chromatography. Typically, purified and bleached beeswax is used in the food, cosmetic, and pharmaceutical industries. In further detail, the types of beeswax used may be classified further by three main types, namely yellow beeswax, white beeswax, and beeswax absolute. Yellow beeswax is the crude product obtained from the honeycomb, white beeswax is bleached or filtered yellow beeswax, and beeswax absolute is typically yellow beeswax treated with alcohol. Beeswax in the transdermal compositions of the present disclosure can have benefits to not only the skin and / or mucosal surface to which it is applied, e.g., lip balm or gloss, skin creams, skin salves, skin moisturizers, etc., but when included, can have the benefit of locking in the other ingredients into the transdermal composition. For example, in addition to the anti-inflammation properties, anti-oxidant properties, and moisturizing / softening properties, protective properties, e.g., burns, rashes, etc., beeswax acts to assist other ingredients in their efficacy and / or longevity once applied, such as for example assisting with the function of the major carrier, e.g., coconut oil and / or butter. Though beeswax works well as a carrier (with the coconut oil and / or butter) and also provides healing and / or protective functions when applied to the skin, in some instances, there may be a benefit to adding another type of wax and / or a blend of beeswax with another type of wax. Examples include candelilla wax, which can be used to modulate the physical properties of the beeswax, which can be useful when preparing a transdermal composition having certain physical properties, e.g., viscosity, spreadability, homogeneity or consistency, etc. Dragon’s blood may also be included in the transdermal compositions. The dragon’s blood may be from any plant source suitable for collecting dragon’s blood, and can be included at from about 0.1 wt% to about 3 wt%, from about 0.2 wt% to about 2.5 wt%, or from about 0.3 wt% to about 2 wt%. Dragon’s blood is typically a bright red resin that can be prepared from a number of plants, but in modern times, it is typically prepared from either Dracaena or Calamus resins. Resins harvested from Calamus are more typical, and are often in the form of large balls of resin. Dragon’s blood, if included, has health benefits related to wound healing, antibacterial treatment, ulcer prevention, anti-aging, etc. If included, dragon’s blood may also provide an improved aroma to the transdermal composition. Example Embodiments In accordance with the disclosure herein, the following examples are illustrative of several embodiments of the present technology. 1. A transdermal composition, comprising: a cannabis particulate blend including THCA, CBD, and male and female reproductive cells, wherein the cannabis particulate blend has a particle size distribution within a range of about 120 µm to about 400 µm, and wherein the THCA is present in the transdermal composition at from about 0.01 wt% to about 0.5 wt% THCA and the CBD is present in the transdermal composition at from about 1 wt% to about 10 wt% CBD; from about 1 wt% to about 10 wt% lion’s mane mushroom; from about 1 wt% to about 10 wt% blackberry; and from about 50 wt% to about 85 wt% coconut oil, coconut butter, or a combination thereof. 2. The transdermal composition of example 1, further comprising from about 0.001 wt% to about 0.2 wt% of one or more B-complex vitamins based on total B- complex vitamin content. 3. The transdermal composition of one of examples 1 to 2, further comprising from about 0.005 wt% to about 0.1 wt% of potassium based on potassium content. 4. The transdermal composition of one of examples 1 to 3, further comprising from about 1 wt% to about 10 wt% ginkgo leaf. 5. The transdermal composition of one of examples 1 to 4, further comprising from about 5 wt% to about 20 wt% beeswax. 6. The transdermal composition of one of examples 1 to 5, further comprising from about 0.1 wt% to about 3 wt% dragon’s blood from Dracaena resin, Calamus resin, or combination thereof. 7. The transdermal composition of one of examples 1 to 6, wherein the THCA is present in the transdermal composition at from about 0.01 wt% to about 0.1 wt%. 8. The transdermal composition of one of examples 1 to 7, wherein cannabis particulate blend has a particle size distribution from about 160 µm to about 400 µm. 9. The transdermal composition of one of examples 1 to 8, wherein the cannabis particulate blend has an average particle size from about 180 µm to about 320 µm by particle count. 10. The transdermal composition of one of examples 1 to 9, wherein the cannabis particulate blend includes particles from both a male plant and a female plant at a weight ratio from about 9:1 to about 1:9. 11. The transdermal composition of one of examples 1 to 10, wherein the cannabis particulate blend includes particles from both a male plant and a female plant at a weight ratio from about 2:1 to about 1:2. 12. The transdermal composition of one of examples 1 to 11, wherein the CBD is present in the transdermal composition at from about 2 wt% to about 8 wt%. 13. The transdermal composition of one of examples 1 to 12, wherein the transdermal composition further includes cocoa butter, shea butter, algae body butter, jojoba butter, cupuacu butter, hemp oil, coconut oil, almond oil, sunflower seed oil, olive oil, avocado oil, argan oil, rosehip see oil, grape seed oil, fish oil, palm oil, anise oil, apricot oil, cassia oil, castor oil, cinnamon oil, clove oil, coriander oil, corn oil, cottonseed oil, eucalyptus oil, lemon oil, lime oil, limonene, nutmeg oil, orange oil, peanut oil, peppermint oil, , phenol, pine needle oil, polypropylene glycol, sesame oil, spearmint oil, soybean oil, vegetable oil, abyssinica oil, macadamia nut oil, limnanthes alba seed oil, aloe vera, petrolatum, candelilla wax, or a combination thereof. 14. The transdermal composition of one of examples 1 to 13, wherein the transdermal composition is formulated to penetrate through the skin to treat a condition within the body beneath the skin. 15. The transdermal composition of one of examples 1 to 14, wherein the transdermal composition is formulated to treat a skin condition by at least transepidermal absorption into the skin through the epidermis. 16. A method of treating a subject, comprising applying a transdermal composition to a skin region, wherein the transdermal composition comprises: a cannabis particulate blend including THCA, CBD, and male and female reproductive cells, wherein the cannabis particulate blend has a particle size distribution within a range of about 120 µm to about 400 µm, and wherein the THCA is present in the transdermal composition at from about 0.01 wt% to about 0.5 wt% THCA and the CBD is present in the transdermal composition at from about 1 wt% to about 10 wt% CBD; from about 1 wt% to about 10 wt% lion’s mane mushroom; from about 1 wt% to about 10 wt% blackberry; and from about 50 wt% to about 85 wt% coconut oil, coconut butter, or a combination thereof. 17. The method of example 16, further comprising heating the skin region within 2 minutes of applying the transdermal composition. 18. The method of one of examples 16 to 17, further comprising from about 0.001 wt% to about 0.2 wt% of one or more B-complex vitamins based on total B-complex vitamin content. 19. The method of one of examples 16 to 18, further comprising from about 0.005 wt% to about 0.1 wt% of potassium based on potassium content. 20. The method of one of examples 16 to 19, further comprising from about 1 wt% to about 10 wt% ginkgo leaf. 21. The method of one of examples 16 to 20, further comprising from about 5 wt% to about 20 wt% beeswax. 22. The method of one of examples 16 to 21, further comprising from about 0.1 wt% to about 3 wt% dragon’s blood from Dracaena resin, Calamus resin, or combination thereof. 23. The method of one of examples 16 to 22, wherein the THCA is present in the transdermal composition at from about 0.01 wt% to about 0.1 wt% and the CBD is present in the transdermal composition at from about 2 wt% to about 8 wt%. 24. The method of one of examples 16 to 23, wherein the cannabis particulate blend has a particle size distribution from about 160 µm to about 400 µm and an average particle size from about 180 µm to about 320 µm by particle count. 25. The method of one of examples 16 to 24, wherein the THCA particles from both the male plant and the female plant are present at a weight ratio from about 2:1 to about 1:2. 26. The method of one of examples 16 to 25, wherein the skin region is affected by the skin condition, wherein the transdermal composition provides at least transepidermal absorption into the skin through the epidermis. 27. The method of one of examples 16 to 26, wherein treating the subject includes transdermally treating non-skin tissue directly beneath the skin region. 28. The method of one of examples 16 to 27, wherein treating the subject includes transdermally treating a systemic condition including at locations remote from directly beneath the skin region. 29. The method of example 28, wherein the skin region is directly at or over a human body chakra. 30. The method of one of examples 16 to 29, wherein treating the subject includes ameliorating wrinkles, symptoms associated with aging, or scars at the skin region. 31. The method of one of examples 16 to 30, wherein treating the subject includes increasing metabolism or enhancing immunity. 32. The method of one of examples 16 to 31, wherein treating the subject includes ameliorating or healing bone pain, joint pain, arthritis, or neuropathic pain. 33. The method of one of examples 16 to 32, wherein treating the subject includes reducing symptoms associated with heart disease. 34. The method of one of examples 16 to 33, wherein treating the subject includes reducing symptoms associated with head trauma. 35. The method of one of examples 16 to 34, wherein treating the subject includes reducing symptoms associated with cancer. 36. A method of making a transdermal composition, comprising: preparing a cannabis particulate blend with enhanced CBD content, THCA content, and reproductive organ content by: freezing both male and female cannabis plants, crushing the male and female cannabis plant, and removing cannabis particulates less than about 120 µm in particle size and greater than about 400 µm in particle size, thereby leaving behind the cannabis particulate blend having a particle size range from about 120 µm to about 400 µm and having enhanced CBD content, THCA content, and reproductive organ content, wherein the cannabis particulate blend is substantially devoid of THC; and combining the cannabis particulate blend with lion’s mane mushroom; blackberry; and coconut oil, coconut butter, or a combination thereof. 37. The method of example 36, wherein removing the cannabis particulates that are less than about 120 µm is carried out using a strainer having a mesh size from about 120 µm to about 160 µm. 38. The method of one of examples 36 to 37, comprising removing cannabis particulates less than about 160 µm in particle size. 39. The method of one of examples 36 to 37, having a formulation including: from about 0.01 wt% to about 0.5 wt% THCA; from about 1 wt% to about 10 wt% CBD; from about 1 wt% to about 10 wt% lion’s mane mushroom; from about 1 wt% to about 10 wt% blackberry; and from about 50 wt% to about 85 wt% coconut oil and / or butter. 40. The method of one of examples 36 to 39, having a formulation including one or more of: from about 0.001 wt% to about 0.2 wt% of one or more B-complex vitamins; from about 0.005 wt% to about 0.1 wt% of potassium; from about 1 wt% to about 10 wt% ginkgo leaf; from about 5 wt% to about 20 wt% beeswax; or from about 0.1 wt% to about 3 wt% dragon’s blood. 41. The method of one of examples 36 to 39, having a formulation including: from about 0.001 wt% to about 0.2 wt% of one or more B-complex vitamins; from about 0.005 wt% to about 0.1 wt% of potassium; from about 1 wt% to about 10 wt% ginkgo leaf; from about 5 wt% to about 20 wt% beeswax; and from about 0.1 wt% to about 3 wt% dragon’s blood. Definitions In describing and claiming the present technology, the following terminology will be used. The singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, reference to “an additive” includes reference to one or more of such components, “a solution” includes reference to one or more of such materials, and “a mixing step” refers to one or more of such steps. As used herein, “substantial” when used in reference to a quantity or amount of a material, or a specific characteristic thereof, refers to an amount that is sufficient to provide an effect that the material or characteristic was intended to provide. The exact degree of deviation allowable may in some cases depend on the specific context. As used herein, “about” refers to a degree of deviation based on experimental error typical for the particular property identified. The latitude provided by the term “about” will depend on the specific context and particular property and can be readily discerned by those skilled in the art. The term “about” is not intended to either expand or limit the degree of equivalents which may otherwise be afforded a particular value. Further, unless otherwise stated, the term “about” expressly includes “exactly,” consistent with the discussion below regarding ranges and numerical data. Concentrations, dimensions, amounts, and other numerical data may be presented herein in a range format. It is to be understood that such range format is used merely for convenience and brevity and should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. For example, a range of about 1 to about 200 should be interpreted to include not only the explicitly recited limits of 1 and 200, but also to include individual sizes such as 2, 3, 4, and sub-ranges such as 10 to 50, 20 to 100, etc. As used herein, a plurality of items, structural elements, compositional elements, and / or materials may be presented in a common list for convenience. However, these lists should be construed as though each member of the list is individually identified as a separate and unique member. Thus, no individual member of such list should be construed as a de facto equivalent of any other member of the same list solely based on their presentation in a common group without indications to the contrary. As used herein, the terms “treatment” or “treating” of a condition and / or a disease in a mammal, means preventing the condition or disease, that is, avoiding any clinical symptoms of the disease; inhibiting the condition or disease, that is, arresting the development or progression of clinical symptoms; and / or relieving the condition or disease, that is, causing the regression of clinical symptoms and / or healing. “Treating” also includes the use of the transdermal compositions described herein for detoxification, rebuilding immunity, etc. “Transdermal” routes of administration include application to a skin or mucosal body surface, and may result in absorption of active ingredients into the skin, through the skin (to underlying tissue or systemic circulation), into mucosal tissue, through mucosal tissue, etc. EXAMPLES The following examples illustrate embodiments of the disclosure that are presently best known. However, it is to be understood that the following are only exemplary or illustrative of the application of the principles of the present technology. Numerous modifications and alternative compositions, methods, and systems may be devised by those skilled in the art without departing from the spirit and scope of the present disclosure. The appended claims are intended to cover such modifications and arrangements. Thus, while the present disclosure has been described above with particularity, the following examples provide further detail in connection with what are presently deemed to be practical embodiments of the disclosure. Example 1 – Preparation of Transdermal Compositions Example transdermal compositions (TDC1-TDC6) are prepared in accordance with the formulations provided in Table 1, as follows: Table 1 – Transdermal Formulations Ingredient TDC1 TDC2 TDC3 TDC4 TDC5 TDC6 Coconut Oil - 10 70 50 80 50 In accordance with the transdermal compositions shown in Table 1, e.g., TDC1-TDC6, these all may be prepared by freezing both male and female cannabis and then washing it with ice water. The cannabis is then extracted down to the size of about 160 µm and greater using a screen or strainer. The other active ingredients are then added, as applicable (shown in Table 1). With respect to the blackberries, that ingredient is added after being juiced. When included, the potassium was added in the form of Potassium Ionic Liquid Electrolyte having about 2 wt% potassium content. Likewise, when included, the B-complex vitamins were added from a Vitamin B-complex solution or suspension having about 1.3 wt% B-complex vitamins. The vitamin B-complex solution or suspension used notably also included about 2.5 wt% vitamin C in addition to the B- complex vitamins. Once the active ingredients are admixed, the composition is then placed in a churn where it is mixed with the coconut oil and / or butter, shea butter, beeswax, and / or candelilla wax, and then the complete composition is loaded into a heating pot, e.g., rice cooker, to infuse the CBD and the THCA into the composition as a whole. The temperature at which THCA is converted to THC is about 105 °C to about 115 °C, so provided the temperature is held below about 105 °C, the THCA will not convert to THC. Thus, in these examples, the temperature of the rice cooker is set to warm (which is well below 100 °C) where the product is heated for about two (2) days. After heating, a 400 µm screen or strainer is then used to remove particles larger than about 400 µm in size. Example 2 – Treatment of Brain Injury or Head Trauma A subject who had experienced head trauma a few years ago had ongoing symptoms related to the injury, including early onset dementia, mood swings, vertigo, headaches, lack of body control, etc. The subject was officially declared disabled by a medical doctor. The subject applied 0.1 gram of the transdermal composition TDC3 shown in Table 3 above daily to the scalp, and after a period of about 3 weeks, most symptoms including loss of motor skills, muscle control, speech, vertigo, and mood swings were at least partially ameliorated. Furthermore, by about 6 months of daily treatment, all motor skills, muscle control, speech, vertigo, and mood swings were cured, with the subject living symptom free for a period of about 18 months to date. Example 3 – Treatment of Arthritis A subject under 50 who had only been experiencing arthritis for a short period of time was treated with a transdermal composition of the present disclosure. The subject applied 1 gram of the transdermal composition directly over the site of the arthritis on a daily basis. After just one treatment, the stiffness and pain associated with the arthritis was significantly reduced, so the subject continued daily application and continued to feel relief associated with topical application over the site of the arthritis. As a second study, a husband and wife in their late 60s who had both been experiencing arthritis for many years were treated with 1 gram of the transdermal composition directly over the site of the arthritis on a daily basis, and furthermore, about 1 gram of the transdermal composition was also applied to various chakra points associated with the location of the arthritis stiffness and pain. The husband and wife reported some relief of the stiffness and pain, but particularly after a period of about 6-8 weeks, the stiffness and pain were significantly reduced. Example 4 – Treatment of Heart Disease A subject with heart disease is treated with one or more of the transdermal compositions described in Table 1. For this treatment, the subject applies from about 0.2 grams of the transdermal composition daily to the chest (or heart chakra). In some instances, application to other chakra points can be periodically substituted for application, such as to the crown chakra, the third eye chakra, the throat chakra, the solar plexus chakra, the sacral chakra, or root chakra. More specific locations may be at the back of the neck, the back of the head, the scalp, the chest, the stomach, etc. After a period of 3-4 months, medical tests indicated great improvement in the cardiovascular health and medical intervention was ceased, while the subject continued living symptom free. Example 5 – Treatment of Bone and Joint Pain A subject with bone and joint pain in the wrist and neck is treated with one or more of the transdermal compositions described in Table 1. For this treatment, the subject applies from about 1 gram of the transdermal composition daily or twice daily to the skin region directly over the wrist pain and the neck pain. Some immediate relief may occur, and the level of relief can continue to increase over a period of weeks. Example 6 – Treatment of Wrinkles and Scarring A subject with wrinkles related to aging and a skin scar is treated with one or more of the transdermal compositions described in Table 1. More specifically, the subject applies a thin layer of the transdermal composition to the wrinkles of the face and to the skin scar twice daily. After a period of a few days, but more typically a few weeks, the wrinkles and skin scar are noticeably reduced and the scar tissue became less noticeable. Example 7 – Treatment of Skin Cancer A subject diagnosed with skin cancer is treated with one or more of the transdermal compositions described in Table 1. For this treatment, the subject applies a thin layer of the transdermal composition twice daily to the site of the affected skin site. After a period of a few weeks to a few months, the skin cancer appears to improve or becomes reduced in size. It is to be understood that the above-referenced arrangements are illustrative of the application for the principles of the present disclosure. Thus, while the present technology has been described above in connection with the exemplary embodiments, it will be apparent to those of ordinary skill in the art that numerous modifications and alternative arrangements can be made without departing from the principles and concepts of the disclosure as set forth in the claims.

Claims

CLAIMS What is claimed is:

1. A transdermal composition, comprising: a cannabis particulate blend including THCA, CBD, and male and female reproductive cells, wherein the cannabis particulate blend has a particle size distribution within a range of about 120 µm to about 400 µm, and wherein the THCA is present in the transdermal composition at from about 0.01 wt% to about 0.5 wt% THCA and the CBD is present in the transdermal composition at from about 1 wt% to about 10 wt% CBD; from about 1 wt% to about 10 wt% lion’s mane mushroom; from about 1 wt% to about 10 wt% blackberry; and from about 50 wt% to about 85 wt% coconut oil, coconut butter, or a combination thereof.

2. The transdermal composition of claim 1, further comprising from about 0.001 wt% to about 0.2 wt% of one or more B-complex vitamins based on total B-complex vitamin content.

3. The transdermal composition of claim 1, further comprising from about 0.005 wt% to about 0.1 wt% of potassium based on potassium content.

4. The transdermal composition of claim 1, further comprising from about 1 wt% to about 10 wt% ginkgo leaf.

5. The transdermal composition of claim 1, further comprising from about 5 wt% to about 20 wt% beeswax.

6. The transdermal composition of claim 1, further comprising from about 0.1 wt% to about 3 wt% dragon’s blood from Dracaena resin, Calamus resin, or combination thereof.

7. The transdermal composition of claim 1, wherein the THCA is present in the transdermal composition at from about 0.01 wt% to about 0.1 wt%.

8. The transdermal composition of claim 1, wherein cannabis particulate blend has a particle size distribution from about 160 µm to about 400 µm.

9. The transdermal composition of claim 1, wherein the cannabis particulate blend has an average particle size from about 180 µm to about 320 µm by particle count.

10. The transdermal composition of claim 1, wherein the cannabis particulate blend includes particles from both a male plant and a female plant at a weight ratio from about 9:1 to about 1:

9.

11. The transdermal composition of claim 1, wherein the cannabis particulate blend includes particles from both a male plant and a female plant at a weight ratio from about 2:1 to about 1:

2.

12. The transdermal composition of claim 1, wherein the CBD is present in the transdermal composition at from about 2 wt% to about 8 wt%.

13. The transdermal composition of claim 1, wherein the transdermal composition further includes cocoa butter, shea butter, algae body butter, jojoba butter, cupuacu butter, hemp oil, coconut oil, almond oil, sunflower seed oil, olive oil, avocado oil, argan oil, rosehip see oil, grape seed oil, fish oil, palm oil, anise oil, apricot oil, cassia oil, castor oil, cinnamon oil, clove oil, coriander oil, corn oil, cottonseed oil, eucalyptus oil, lemon oil, lime oil, limonene, nutmeg oil, orange oil, peanut oil, peppermint oil, , phenol, pine needle oil, polypropylene glycol, sesame oil, spearmint oil, soybean oil, vegetable oil, abyssinica oil, macadamia nut oil, limnanthes alba seed oil, aloe vera, petrolatum, candelilla wax, or a combination thereof.

14. The transdermal composition of claim 1, wherein the transdermal composition is formulated to penetrate through the skin to treat a condition within the body beneath the skin.

15. The transdermal composition of claim 1, wherein the transdermal composition is formulated to treat a skin condition by at least transepidermal absorption into the skin through the epidermis.

16. A method of treating a subject, comprising applying a transdermal composition to a skin region, wherein the transdermal composition comprises: a cannabis particulate blend including THCA, CBD, and male and female reproductive cells, wherein the cannabis particulate blend has a particle size distribution within a range of about 120 µm to about 400 µm, and wherein the THCA is present in the transdermal composition at from about 0.01 wt% to about 0.5 wt% THCA and the CBD is present in the transdermal composition at from about 1 wt% to about 10 wt% CBD; from about 1 wt% to about 10 wt% lion’s mane mushroom; from about 1 wt% to about 10 wt% blackberry; and from about 50 wt% to about 85 wt% coconut oil, coconut butter, or a combination thereof.

17. The method of claim 16, further comprising heating the skin region within 2 minutes of applying the transdermal composition.

18. The method of claim 16, further comprising from about 0.001 wt% to about 0.2 wt% of one or more B-complex vitamins based on total B-complex vitamin content.

19. The method of claim 16, further comprising from about 0.005 wt% to about 0.1 wt% of potassium based on potassium content.

20. The method of claim 16, further comprising from about 1 wt% to about 10 wt% ginkgo leaf.

21. The method of claim 16, further comprising from about 5 wt% to about 20 wt% beeswax.

22. The method of claim 16, further comprising from about 0.1 wt% to about 3 wt% dragon’s blood from Dracaena resin, Calamus resin, or combination thereof.

23. The method of claim 16, wherein the THCA is present in the transdermal composition at from about 0.01 wt% to about 0.1 wt% and the CBD is present in the transdermal composition at from about 2 wt% to about 8 wt%.

24. The method of claim 16, wherein the cannabis particulate blend has a particle size distribution from about 160 µm to about 400 µm and an average particle size from about 180 µm to about 320 µm by particle count.

25. The method of claim 16, wherein the THCA particles from both the male plant and the female plant are present at a weight ratio from about 2:1 to about 1:

2.

26. The method of claim 16, wherein the skin region is affected by the skin condition, wherein the transdermal composition provides at least transepidermal absorption into the skin through the epidermis.

27. The method of claim 16, wherein treating the subject includes transdermally treating non-skin tissue directly beneath the skin region.

28. The method of claim 16, wherein treating the subject includes transdermally treating a systemic condition including at locations remote from directly beneath the skin region.

29. The method of claim 28, wherein the skin region is directly at or over a human body chakra.

30. The method of claim 16, wherein treating the subject includes ameliorating wrinkles, symptoms associated with aging, or scars at the skin region.

31. The method of claim 16, wherein treating the subject includes increasing metabolism or enhancing immunity.

32. The method of claim 16, wherein treating the subject includes ameliorating or healing bone pain, joint pain, arthritis, or neuropathic pain.

33. The method of claim 16, wherein treating the subject includes reducing symptoms associated with heart disease.

34. The method of claim 16, wherein treating the subject includes reducing symptoms associated with head trauma.

35. The method of claim 16, wherein treating the subject includes reducing symptoms associated with cancer.

36. A method of making a transdermal composition, comprising: preparing a cannabis particulate blend with enhanced CBD content, THCA content, and reproductive organ content by: freezing both male and female cannabis plants, crushing the male and female cannabis plant, and removing cannabis particulates less than about 120 µm in particle size and greater than about 400 µm in particle size, thereby leaving behind the cannabis particulate blend having a particle size range from about 120 µm to about 400 µm and having enhanced CBD content, THCA content, and reproductive organ content, wherein the cannabis particulate blend is substantially devoid of THC; and combining the cannabis particulate blend with lion’s mane mushroom; blackberry; and coconut oil, coconut butter, or a combination thereof.

37. The method of claim 36, wherein removing the cannabis particulates that are less than about 120 µm is carried out using a strainer having a mesh size from about 120 µm to about 160 µm.

38. The method of claim 36, comprising removing cannabis particulates less than about 160 µm in particle size.

39. The method of claim 36, having the following formulation: from about 0.01 wt% to about 0.5 wt% THCA; from about 1 wt% to about 10 wt% CBD; from about 1 wt% to about 10 wt% lion’s mane mushroom; from about 1 wt% to about 10 wt% blackberry; and from about 50 wt% to about 85 wt% coconut oil and / or butter.

40. The method of claim 39, further comprising one or more of: from about 0.001 wt% to about 0.2 wt% of one or more B-complex vitamins; from about 0.005 wt% to about 0.1 wt% of potassium; from about 1 wt% to about 10 wt% ginkgo leaf; from about 5 wt% to about 20 wt% beeswax; or from about 0.1 wt% to about 3 wt% dragon’s blood.

41. The method of claim 39, further comprising: from about 0.001 wt% to about 0.2 wt% of one or more B-complex vitamins; from about 0.005 wt% to about 0.1 wt% of potassium; from about 1 wt% to about 10 wt% ginkgo leaf; from about 5 wt% to about 20 wt% beeswax; and from about 0.1 wt% to about 3 wt% dragon’s blood.

Images